


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4419850/publications.pdf Version: 2024-02-01



ΙιλΝΙ Χιι

#	Article	IF	CITATIONS
1	Antibody–Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Advanced Biology, 2022, , 2101065.	2.5	4
2	Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Cancer Communications, 2022, 42, 269-272.	9.2	3
3	Nanocarrierâ€delivered small interfering <scp>RNA</scp> for chemoresistant ovarian cancer therapy. Wiley Interdisciplinary Reviews RNA, 2021, 12, e1648.	6.4	8
4	Advances and challenges in the treatment of esophageal cancer. Acta Pharmaceutica Sinica B, 2021, 11, 3379-3392.	12.0	101
5	Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular Cancer Therapeutics, 2021, 20, 2082-2092.	4.1	1
6	Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials, 2021, 33, e2103114.	21.0	6
7	Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination. Molecular Pharmaceutics, 2021, 18, 1397-1407.	4.6	5
8	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
9	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 2020, 10, 973.	4.0	16
10	Albuminâ€Mediated Delivery of Bioactive Peptides for Pancreatic Cancer Therapy. Advanced Therapeutics, 2020, 3, 2000003.	3.2	3
11	CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. Cell Cycle, 2019, 18, 452-466.	2.6	10
12	Nanoparticle systems for cancer vaccine. Nanomedicine, 2019, 14, 627-648.	3.3	85
13	Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. Drug Delivery, 2018, 25, 102-111.	5.7	5
14	Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma. Laboratory Investigation, 2018, 98, 1538-1548.	3.7	10
15	EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis. Acta Pharmacologica Sinica, 2018, 39, 1777-1786.	6.1	20
16	Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget, 2018, 9, 5459-5472.	1.8	47
17	Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study. RSC Advances, 2017, 7, 4763-4775.	3.6	12
18	Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacological Research, 2017, 126, 66-76.	7.1	28

Jian Xu

#	Article	IF	CITATIONS
19	A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity. Scientific Reports, 2017, 7, 5093.	3.3	21
20	An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget, 2015, 6, 26322-26334.	1.8	23